The amount of people with psoriasis who develop psoriatic arthritis ranges widely between 6 and 42 percent. According to AAD, symptoms include: Eczema and psoriasis are different chronic conditions, ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...

Rheumatic diseases make up a collection of arthritis subtypes, but also include fibromyalgia, Sjogren's syndrome, and more.

FDA alerts in gastroenterology over the summer included an approval for a biosimilar for IBD & new indications for nonerosive GERD and PFIC.

Juvenile idiopathic arthritis symptoms may only affect certain joints. Some children have systemic reactions, such as rash.

Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are lifelong conditions that can have a significant impact on those ...

“There are many options to treat psoriatic arthritis, like COSENTYX, which may help provide relief and reduce symptoms ...

Importantly, however, a large portion of care for rheumatic diseases to date is based on the established paradigm of diagnosis and initiation of therapy when an individual is identified as having an ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

The global psoriasis therapeutics market revenue was around US$ 25.0 billion in 2022 and is estimated to reach US$ 55.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.3% during ...